Dual Roles of β -Oxodithioesters in the Copper-Catalyzed Synthesis of Benzo[*e*]pyrazolo[1,5-*c*][1,3]thiazine Derivatives

Li-Rong Wen,* Wen-Kui Yuan, and Ming Li*

State Key Laboratory Base of Eco-Chemical Engineering, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, China

Supporting Information



ABSTRACT: A facile and efficient method for the chemoselective synthesis of benzo[e]pyrazolo[1,5-c][1,3]thiazine derivatives has been developed by tandem Ullmann coupling reactions of β -oxodithioesters (ODEs) with 3-(2-bromoaryl)-1*H*-pyrazoles in C–S bond formation manner, in which ODEs play dual roles as both a substrate and a ligand. A series of benzo[e]pyrazolo[1,5-c][1,3]thiazine derivatives were provided in good to excellent yields with CuI as the copper source in the presence of NaOH in CH₃CN at 80 °C under a N₂ atmosphere.

INTRODUCTION

The 1,3-benzothiazine skeleton is a key structural element that appears in the core structures of pharmaceutically relevant compounds. For example, PD 404182 (Figure 1, A) has been



Figure 1. Examples of bioactive 1,3-benzothiazines.

reported as an antimicrobial agent that inhibits 3-deoxy-Dmanno-octulosonic acid 8-phosphate synthase¹ and phosphopantetheinyl transferase,² and could be used as an antiretroviral agent with submicromolar inhibitory activity against human immunodeficiency virus-1 (HIV-1) and HIV-2 infection.³ Compounds **B** have demonstrated anntimalarial activity against *Plasmodium falciparum* in vitro and *Plasmodium yoelii* in vivo.⁴ Compound **C** can be used as sedatives.⁵ Compound **D** has been studied as a promising inhibitor of nitric oxide synthase in the treatment of inflammatory disease and pain.⁶ Other interesting 1,3-benzothiazine derivatives have also been investigated as antibacterials,⁷ cell growth inhibitors,⁸ and HIV-RT inhibitory activity.⁹ Although 1,3-benzothiazine derivatives play important roles in biological and medicinal areas, few approaches to these compounds have been developed to date.¹⁰ These methods may suffer from tedious procedures, poor precursor scopes, or low efficiency. So, there are still opportunities for the development of novel procedures for the synthesis of new and interesting 1,3-benzothiazine derivatives.

The recent advances in cross-coupling reactions using transition-metal catalysis have led to the development of effective methods for the construction of carbon–sulfur bonds.¹¹ For example, palladium,¹² iron,¹³ and copper¹⁴ salts have emerged as appealing catalysts for these reactions. Among the various employed metals, copper is one of the most favorable metals for C–S bond forming reactions due to its low cost and low toxicity.¹⁵ Most of these copper-catalyzed reactions involve specially designed ligands or well-defined catalysts/reagents, which may increase the cost and limit the scope of applications in some cases.

scope of applications in some cases. β -Oxodithioesters (ODEs)¹⁶ have been employed to construct various important bioactive frameworks, such as thiophene,¹⁷ pyrrole,¹⁸ 4*H*-thiopyran,¹⁹ thiazole,²⁰ 1,3-oxathiole,²¹ pyrazole,²² 1,3,4-thiadiazole,²³ dihydropyrimidinone,²⁴ and chromene- 2-thione.²⁵ However, all of the above protocols did not involve the thiocarbonyl-based Ullmann coupling reactions catalyzed by copper. In continuation of our ongoing research interest in the synthesis of heterocycles,²⁶ we herein report a first example of a concise copper-catalyzed tandem reaction of β -oxodithioesters (1) with 3-(2-bromoaryl)-1*H*pyrazoles (2) for the synthesis of benzo[*e*]pyrazolo[1,5-

Received: February 6, 2015 Published: April 20, 2015



Figure 2. Reactive sites of β -oxodithioesters.

c][1,3]thiazines (3), in which ODEs (1) play dual roles as both a substrate and a ligand.

RESULTS AND DISCUSSION

The chemical properties of β -oxodithioester (1) can be featured by the presence of two electrophilic and three nucleophilic (one potential) centers as shown in Figure 2.

Due to the presence of these active centers, the reactions of ODEs (1) with various difunctional group reagents may lead to the formation of various heterocyclic systems, where the sulfur atom is present in the ring system or as an external substituent. There are two possible coupling modes when ODEs (1) react with 3-(2-bromoaryl)-1*H*-pyrazoles (2) under Cu catalysis (Scheme 1). In mode A, the S atom of the thiocarbonyl group

Scheme 1. Two Possible Copper-Catalyzed Coupling Modes Involving β -Oxodithioesters



in ODEs (1) participates in an Ullmann coupling reaction with 3-(2-bromoaryl)-1*H*-pyrazoles (2) providing benzo[e]pyrazolo-[1,5-c][1,3] thiazines (3). In mode B, the coupling reactions occur in the methylene of ODEs (1), providing pyrazolo[5,1*a*]isoquinolines (3') through a Hurtley coupling reaction.^{26c}Under our reaction conditions only 3 were obtained exclusively,and 3' were not observed, which suggested that our protocolshows high chemoselectivity.

Optimization of the reaction conditions was carried out with methyl 3-oxo-3-phenylpropanedithioate (1a) and 5-(2-bromophenyl)-*N*-phenyl-1*H*- pyrazol-3-amine (2a) as model substrates under a N_2 atmosphere, and the results are shown in Table 1.

As shown in Table 1, in the absence of catalyst, no reaction was observed at room temperature in the presence of NaOH in CH₃CN under a N₂ atmosphere for 5 h (Table 1, entry 1). But after addition of CuI (0.1 equiv), the product **3a** was obtained in a yield of 25% (Table 1, entry 2). The yield of **3a** was greatly improved with increasing the reaction temperature (Table 1, entries 3 and 4), and the yield of **3a** reached 91% at reflux temperature. Then other solvents such as EtOH, dioxane, toluene, DMSO, and DMF were also investigated at reflux temperature (Table 1, entries 5–9), and the results revealed

Table 1. Reaction Condition Optimization^a

		D			PhHN	
0	S		HPh Catal	yst, L , base, N ₂	N-	-N
Ph	SCH ₃ +	N-NH	so	lvent, temp	-	∕ s
1a	1	2a				
			h			3a
entry	base	Cu salt (equiv)	L^{ν} (equiv)	solvent	T/°C	yield ^c /%
1	NaOH		· · /	CH ₂ CN	rt	NR ^d
2	NaOH	CuI (0.1)		CH.CN	rt	25
3	NaOH	CuI(0.1)		CH ₂ CN	60	20 75
4	NaOH	CuI(0.1)		CH ₂ CN	80	91
5	NaOH	CuI(0.1)		EtOH	reflux	56
6	NaOH	CuI(0.1)		dioxane	reflux	85
7	NaOH	CuI(0.1)		toluene	reflux	78
8	NaOH	CuI(0.1)		DMSO	reflux	73
9	NaOH	CuI(0.1)		DMF	reflux	67
10	Na ₂ CO ₂	CuI (0.1)		CH ₂ CN	80	53
11	Cs ₂ CO ₂	CuI(0.1)		CH ₂ CN	80	78
12	Et ₃ N	CuI (0.1)		CH ₃ CN	80	30
13	DABCO	CuI (0.1)		CH ₃ CN	80	46
14	NaOH	CuI (0.1)	LI	CH ₃ CN	80	88
		<i>.</i>	(0.2)			
15	NaOH	CuI (0.1)	L2 (0.2)	CH ₃ CN	80	90
16	NaOH	CuI (0.1)	L3	CH ₃ CN	80	55
		<i>,</i> ,	(0.2)			
17	NaOH	CuI (0.1)	L4 (0.2)	CH ₃ CN	80	76
18	NaOH	CuI (0.1)	L5	CH ₃ CN	80	88
			(0.2)			
19	NaOH	CuI (0.1)		CH ₃ CN	80	83 ^e
20	NaOH	CuI (0.1)		CH ₃ CN	80	90'
21	NaOH	CuBr (0.1)		CH ₃ CN	80	78
22	NaOH	CuCl (0.1)		CH ₃ CN	80	64
23	NaOH	$Cu_2O(0.1)$		CH ₃ CN	80	20
24	NaOH	$\begin{array}{c} { m CuSO}_4 \\ (0.1) \end{array}$		CH ₃ CN	80	35
25	NaOH	CuI (0.05)		CH ₃ CN	80	70
26	NaOH	CuI (0.2)		CH ₃ CN	80	87
27	NaOH (1.0)	CuI (0.1)		CH ₃ CN	80	42
28	NaOH (3.0)	CuI (0.1)		CH_3CN	80	89

"Reaction conditions: 1a (0.6 mmol), 2a (0.5 mmol), base (1.0 mmol), solvent (2 mL), N_2 , 5 h. ^bThe structures of the ligands are as follows:



^cIsolated yield. ^dNo reaction. ^e1a (0.55 mmol) was used. ^f1a (0.65 mmol) was used.

4943

Table 2. Investigation on the Substrate $Scope^{a}$



^{*a*}Reaction conditions: **1** (0.6 mmol), **2** (0.5 mmol), NaOH (1.0 mmol), CuI (0.05 mmol), CH₃CN (2.0 mL), N₂, 5 h. ^{*b*}Isolated yields were based on **2**.

that CH₃CN was most suitable. Next, various bases such as Na_2CO_3 , Cs_2CO_3 , Et_3N , and DABCO were tested (Table 1, entries 10–13), but they gave lower yields than NaOH.

With regard to most copper-catalyzed reactions generally involving the use of ligands, the model reaction was performed in CH₃CN with different ligands such as L1-L5 (Table 1, entries 14-18). Unfortunately, these ligands did not further improve the yield of 3a. This observation prompted us to investigate the amount of 1a. The results revealed that when 10% excess of 1a was used, the yield of 3a decreased (Table 1, entry 19), while 30% excess of 1a did not further improve the yield of 3a (Table 1, entry 20), which suggested that 20% excess of 1a might act as a ligand for this copper-catalyzed coupling reaction. Other copper sources such as CuBr, CuCl, Cu_2O , and $CuSO_4$ were also screened (Table 1, entries 21–24), and the results showed that CuI was most efficient for this coupling reaction. Increasing or decreasing the amount of CuI did not improve the yield of 3a (Table 1, entries 25 and 26). Finally, the amount of NaOH was also examined (Table 1, entries 27 and 28), and the results showed that 2 equiv of NaOH is most suitable for the transformation. Therefore, the optimized conditions for this coupling reaction are as follows: 0.1 equiv of CuI as the copper source, 2.0 equiv of NaOH as the base, and CH₃CN as the solvent at 80 °C under a N₂ atmosphere.

With the above optimized reaction conditions in hand, we commenced to explore the substrate scope, and the results are summarized in Table 2. As expected, other halides such as chloride (2b) and fluoride (2c) provided lower yields (Table 2, entries 2 and 3).

As can be seen from Table 2, all of the tandem reactions proceeded smoothly to give corresponding products 3 in good to excellent yields. For substrates 1, a wide range of aromatic β oxodithioesters bearing electron-withdrawing or electrondonating groups (Table 2, entries 1–13), even aliphatic β oxodithioester (Table 2, entry 14) and heterocyclic β oxodithioester (Table 2, entry 15), could be well tolerated. For substrates 2, the substituents at the 5-position on the pyrazole ring have evident influence on the reaction yields. For example, arylamino substituents bearing either electron-withdrawing or electron-donating groups gave excellent yields of 89-94% (Table 2, entries 1, 20-22); a primary amino substituent provided the relatively low yield of 84% (Table 2, entry 16); while 5-unsubstituted 3-(2-bromophenyl)-1Hpyrazole (2e) could lead to the even lower yield of 76% (Table 2, entry 17), and the introduction of a fluorine atom to the phenyl ring linked directly to pyrazole could improve slightly the reaction yields (3a vs 3p, 3d vs 3q, and 3g vs 3r).

The structural characterization of products 3 was achieved by spectroscopic data (¹H and ¹³C NMR, IR, and HRMS) and unequivocally established by the X-ray single crystal diffraction analysis of compound $3\mathbf{k}$ (Figure S1 in the Supporting Information). Moreover, X-ray analysis of $3\mathbf{k}$ reveals that the obtained products take the Z configuration.

In order to explore the role as a ligand of ODEs (1) in this coupling reaction, an attempt to obtain the copper(I)–ODE complex was made. Mass spectrometric (MS-ESI-TOF, $[M + H]^+$) studies of the reaction system of CuI and 1a in CH₃CN in the presence of NaOH at room temperature for 0.5 h exhibited the two ion peaks at m/z 482.94 and 544.84 (Figure S2 in the Supporting Information), which could be due to the mononuclear copper(I) complex II₁ (calcd 482.96) and the dinuclear copper(I) complex II₁ (calcd 544.88), respectively

(Scheme 2). This observation is in accordance with the report in literature.²⁷ Moreover, the MS analysis suggested that, in the

Scheme 2. Coordination Mode Exploration of CuI with 1a



mononuclear copper(I)–ODE complex (I_{1a}), the two molecules of 1a play different roles: one acts as a dative ligand, and another as an anionic ligand that would be the nucleophilile in the coupling reaction.²⁸

In order to investigate the mechanism of this tandem reaction, a control experiment was carried out. We utilized 3-benzylpyrazole without o-Br group (2') and 3-(o-bromobenzyl)pyrazole (2a) to react with β -oxodithioester 1a under the standard conditions, respectively. As indicated by TLC, the reaction of 2a with 1a provided the target product 3a within 10 min, while the reaction of 2' with 1a did not occur after 30 min; even after 10 h only small amounts of 2' and 1a were consumed. These results reveal that the C-Br bond of 3-(o-bromobenzyl)pyrazole (2a) is easy to be activated by the present copper catalyst to lead to S-arylation with 1a.

On the basis of the experimental results obtained above, a proposed mechanism for the tandem reactions is outlined in Scheme 3. Initially a reaction between substrate β -oxodithioesters 1 and CuI would occur to give complex I, which undergoes an oxidative addition reaction with 2 to yield Cu(III) intermediate **A**. The subsequent reductive elimination releases

Scheme 3. Proposed Reaction Mechanism



intermediate C with the concomitant regeneration of the Cu(I) species B, and in C the dithioester segment still keeps a Z configuration. Finally, C undergoes an intramolecular nucleophilic substitution reaction (S_Ni) to give the final Z-configured products 3.

CONCLUSION

In summary, we have developed a method for the synthesis of benzo[*e*]pyrazolo [1,5-*c*][1,3]thiazine derivatives from substituted 3-(2-bromoaryl)-1*H*-pyrazoles and β -oxodithioesters by a copper-catalyzed intermolecular C–S cross-coupling reaction and an intramolecular nucleophilic substitution reaction in cascade mode. It is the first report on employing β -oxodithioesters as both a substrate and a ligand to construct a pyrazolo[1,5-*c*][1,3]thiazine motif under copper-catalyzed conditions. The advantages of this strategy are high yields, mild reaction conditions, easy purification, and availability of CuI/ extra-ligand-free catalyst.

EXPERIMENTAL SECTION

General Experimental Methods. All reagents and solvents were obtained from commercial suppliers and used without further purification. All reagents were weighed and handled in air at room temperature. Melting points were recorded on a microscopic melting apparatus and uncorrected. ¹H NMR, ¹⁹F NMR, and ¹³C NMR spectra were recorded at 500, 376, and 125 MHz in DMSO-*d*₆, respectively. Chemical shifts are reported in δ (ppm) relative to TMS or CFCl₃. IR spectra were recorded on a FT-IR spectrometer, and only major peaks are reported in cm⁻¹. HRMS spectra were performed on a spectrometer with an ESI source. The X-ray single-crystal diffraction was performed on a CCD area detector. The substrate 5-(2-fluorophenyl)-*N*-phenyl-1*H*-pyrazol-3-amine (**2c**) was prepared according to a reported procedure.²⁹ 3-(2-Bromophenyl)-1*H*-pyrazole (**2e**) was prepared by a reported procedure.³⁰

General Procedure for the Synthesis of Products 3 (3a for Example). Under a nitrogen atmosphere, a mixture of methyl 3-oxo-3-phenylpropanedithioate (1a) (126.2 mg, 0.6 mmol), 3-(2bromophenyl)-*N*-phenyl-1*H*-pyrazol-5-amine (2a) (157.1 mg, 0.5 mmol), and NaOH (40 mg, 1.0 mmol) was heated in the presence of CuI (9.5 mg, 0.05 mmol) in CH₃CN (2 mL) at 80 °C. After completion of the reaction as indicated by TLC, the solid product was filtered, washed with CH₃CN (3 × 5 mL), and subsequently dried to give the pure product 3a.

5-(2-Fluorophenyl)-N-phenyl-1H-pyrazol-3-amine (2c): white solid; mp 93–94 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.49 (1H, s), 7.62 (1H, q, *J* = 7.79 Hz, *J* = 1.58 Hz), 7.31–7.27 (1H, m), 7.25–7.24 (2H, m), 7.17–7.16 (1H, m), 7.13 (3H, d, *J* = 8.45 Hz), 6.88 (1H, t, *J* = 7.30 Hz), 6.42 (1H, s); ¹³C NMR (125 MHz, CDCl₃) δ 159.3 (d, ¹*J*_{C-F} = 248.1 Hz), 151.6, 143.1, 139.0, 129.7 (d, ³*J*_{C-F} = 6.7 Hz), 129.2, 127.8, 124.7, 120.1, 117.3 (d, ³*J*_{C-F} = 11.0 Hz), 116.3 (d, ²*J*_{C-F} = 2.2 Hz), 115.9, 93.4; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ –115.8; IR (KBr, cm⁻¹) ν 3387, 3266, 3156, 3061 1602, 1589, 1576, 1552, 1505, 1469, 1454; HRMS (ESI-TOF, [M + H]⁺) calcd for C₁₅H₁₃N₃F 254.1094, found 254.1098.

(*Z*)-1-Phenyl-2-(2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c]-[1,3]thiazin-5-ylidene)ethan-1-one (**3a**): isolated yield 180 mg (91%); yellowish green solid; mp 267–269 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.53 (1H, s), 8.19 (1H, d, *J* = 7.25 Hz), 7.98 (2H, d, *J* = 6.70 Hz), 7.75 (1H, d, *J* = 7.55 Hz), 7.64–7.60 (5H, m), 7.57– 7.51 (2H, m), 7.37 (2H, t, *J* = 7.00 Hz), 7.04 (1H, s), 6.94 (1H, t, *J* = 6.75 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.2, 154.9, 147.2, 141.9, 139.2, 138.8, 132.6, 130.5, 129.5, 129.4, 128.2, 127.6, 127.1, 126.5, 126.1, 120.8, 120.7, 117.2, 98.5, 95.8; IR (KBr, cm⁻¹) ν 3342, 3048, 1610, 1602, 1576, 1560, 1498, 1485, 1439; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₈N₃OS 396.1171, found 396.1162.

(Z)-2-(2-(Phenylamino)-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)-1-(4-(trifluoromethyl)phenyl)ethan-1-one (**3b**): isolated yield 225 mg (97%); yellowish green solid; mp >300 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.60 (1H, s), 8.21 (2H, d, *J* = 7.55 Hz), 8.16 (2H, d, *J* = 8.00 Hz), 7.98 (2H, d, *J* = 8.05 Hz), 7.93 (1H, s), 7.78 (1H, d, *J* = 7.80 Hz), 7.65 (2H, d, *J* = 8.05 Hz), 7.58–7.51 (2H, m), 7.38 (2H, t, *J* = 7.70 Hz), 7.07 (1H, s), 6.94 (1H, t, *J* = 7.20 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 185.9, 155.2, 148.5, 142.6, 141.9, 138.9, 130.6, 129.6, 128.5, 126.9, 126.6, 126.5, 126.2, 120.9, 120.8, 117.3, 98.2, 96.3; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –61.3; IR (KBr, cm⁻¹) ν 3319, 1615, 1599, 1573, 1557, 1517, 1482, 1441, 1324; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₅H₁₇N₃OSF₃ 464.1044, found 464.1049.

(Z)-1-(4-Fluorophenyl)-2-(2-(phenylamino)-5H-benzo[e]pyrazolo-[1,5-c][1,3]thiazin-5-ylidene)ethan-1-one (**3***c*): isolated yield 196 mg (95%); yellowish green solid; mp 255–256 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.53 (1H, s), 8.18 (1H, s), 8.04 (1H, s), 7.90 (2H, d, J = 7.90 Hz), 7.73 (1H, m), 7.63 (2H, d, J = 7.20 Hz), 7.54–7.50 (2H, m), 7.44–7.38 (4H, m), 7.03 (1H, s), 6.94 (1H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 185.9, 155.1, 147.4, 144.5, 142.1, 139.0, 130.6, 129.6, 128.2, 127.3, 126.7, 126.0, 120.7, 117.5, 116.3 (d, ²J_{C-F} = 21.75 Hz), 98.5, 98.4, 95.9, 95.7; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –107.8; IR (KBr, cm⁻¹) ν 3312, 1598, 1558, 1476, 1439, 1498; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OFS 414.1076, found 414.1086.

(*Z*)-1-(*4*-Chlorophenyl)-2-(2-(phenylamino)-5H-benzo[*e*]pyrazolo[1,5-*c*][1,3]thiazin-5-ylidene)ethan-1-one (**3d**): isolated yield 198 mg (92%); yellowish green solid; mp 262–263 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.54 (1H, s), 8.18 (1H, s), 7.98 (1H, s), 7.88 (1H, s), 7.74–7.65 (5H, m), 7.55–7.51 (2H, m), 7.38 (2H, s), 7.05 (1H, s), 6.95 (1H, s); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 185.9, 155.0, 147.8, 141.9, 138.8, 137.9, 137.4, 130.5, 129.5, 128.2, 127.0, 126.5, 126.1, 120.8, 120.7, 117.2, 98.1, 96.0; IR (KBr, cm⁻¹) ν 3314, 1609, 1598, 1589, 1570, 1557, 1496, 1478, 1440; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OSCl 430.0781, found 430.0775.

(*Z*)-1-(*4*-Bromophenyl)-2-(2-(phenylamino)-5H-benzo[*e*]pyrazolo[1,5-*c*][1,3]thiazin-5-ylidene)ethan-1-one (**3e**): isolated yield 223 mg (94%); yellowish green solid; mp 276–278 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.53 (1H, s), 8.17 (1H, d, *J* = 7.65 Hz), 7.89 (1H, s), 7.87 (2H, d, *J* = 4.15 Hz), 7.79 (2H, d, *J* = 8.35 Hz), 7.73 (1H, d, *J* = 7.80 Hz), 7.62 (2H, d, *J* = 8.05 Hz), 7.55–7.48 (2H, m), 7.36 (2H, t, *J* = 7.75 Hz), 7.03 (1H, s), 6.93 (1H, t, *J* = 7.28 Hz); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 186.3, 154.9, 147.8, 141.9, 138.9, 138.3, 132.4, 130.5, 129.6, 129.5, 128.2, 127.0, 126.5, 126.4, 126.1, 120.8, 120.7, 117.3, 98.1, 96.0; IR (KBr, cm⁻¹) ν 3306, 1601, 1587, 1569, 1558, 1491, 1474, 1438; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OSBr 474.0276, found 474.0285.

(*Z*)-2-(2-(*Phenylamino*)-5*H*-benzo[*e*]*pyrazolo*[1,5-*c*][1,3]*thiazin*-5-*ylidene*)-1-(*p*-tol*yl*)*ethan*-1-one (**3f**): isolated yield 178 mg (87%); yellowish green solid; mp 251–253 °C; ¹H NMR (500 MHz, DMSO d_6) δ 9.51 (1H, s), 8.18 (1H, d, *J* = 7.25 Hz), 7.93 (1H, s), 7.88 (2H, d, *J* = 7.20 Hz), 7.73 (1H, d, *J* = 7.25 Hz), 7.63 (2H, d, *J* = 7.35 Hz), 7.54–7.49 (2H, m), 7.40–7.39 (4H, m), 7.03 (1H, s), 6.94 (1H, s), 2.40 (3H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.0, 154.9, 146.8, 143.0, 142.2, 138.8, 136.7, 130.5, 129.9, 129.6, 128.1, 127.7, 127.2, 126.5, 126.0, 120.8, 117.1, 98.4, 95.6, 21.4; IR (KBr, cm⁻¹) ν 3319, 1598, 1568, 1553, 1519, 1482, 1438, 1405; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₅H₂₀N₃OS 410.1327, found 410.1336.

(*Z*)-1-(4-Methoxyphenyl)-2-(2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)ethan-1-one (**3g**): isolated yield 177 mg (83%); yellowish green solid; mp 246–247 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.50 (1H, s), 8.16 (1H, d, *J* = 7.30 Hz), 7.96 (2H, d, *J* = 8.05 Hz), 7.91 (1H, s), 7.70 (1H, d, *J* = 7.55 Hz), 7.64 (2H, d, *J* = 7.50 Hz), 7.54–7.48 (2H, m), 7.38 (2H, t, *J* = 7.10 Hz), 7.13 (2H, d, *J* = 8.00 Hz), 7.00 (1H, s), 6.94 (1H, t, *J* = 6.70 Hz), 3.86 (3H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 186.0, 162.9, 154.8, 146.3, 142.0, 138.7, 131.9, 130.4, 129.8, 129.5, 128.0, 127.4, 126.4, 126.0, 120.7, 117.2, 114.6, 98.5, 95.6, 56.0; IR (KBr, cm⁻¹) ν 3318, 1601, 1573, 1568, 1482, 1440, 1414 ; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₅H₂₀N₃O₂S 426.1276, found 426.1285.

(Z)-1-(2-Chlorophenyl)-2-(2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)ethan-1-one (**3h**): isolated yield 194 mg (90%); yellowish green solid; mp 244–245 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.48 (1H, s), 8.18 (1H, d, J = 7.50 Hz), 7.76 (1H, d, *J* = 7.70 Hz), 7.66 (1H, d, *J* = 6.35 Hz), 7.63 (1H, s), 7.60–7.57 (3H, m), 7.55–7.47 (4H, m), 7.29 (2H, t, *J* = 7.70 Hz), 7.01 (1H, s), 6.90 (1H, t, *J* = 7.23 Hz); ¹³C NMR (125 MHz, DMSO*d*₆) δ 188.1, 155.0, 147.0, 141.8, 140.4, 138.8, 132.2, 130.8, 130.3, 130.5, 130.1, 129.4, 128.3, 128.0, 126.7, 126.6, 126.1, 120.9, 120.7, 117.1, 102.0, 96.1; IR (KBr, cm⁻¹) ν 3360, 1605, 1570, 1560, 1519, 1485, 1473, 1442, 1408; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OSCI 430.0781, found 430.0776.

(Z)-1-(3-Chlorophenyl)-2-(2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)ethan-1-one (**3i**): isolated yield 196 mg (91%); yellowish green solid; mp 270–272 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.60 (1H, s), 8.15 (1H, s), 7.90 (2H, s), 7.86 (1H, s), 7.66 (5H, s), 7.50 (2H, s), 7.35 (2H, s), 7.04 (1H, s), 6.94 (1H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 185.4, 155.1, 148.0, 141.9, 141.1, 138.8, 134.3, 132.2, 131.4, 130.5, 129.5, 128.3, 127.4, 126.9, 126.6, 126.1, 120.9, 120.7, 117.4, 98.0, 96.1; IR (KBr, cm⁻¹) ν 3323, 1598, 1569, 1557, 1516, 1491, 1472, 1440; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OSCI 430.0781, found 430.0785.

(*Z*)-1-(*2*,4-*Dichlorophenyl*)-2-(2-(*phenylamino*)-5*H*-benzo[*e*]*pyrazolo*[1,5-*c*][1,3]*thiazin*-5-*ylidene*)*ethan*-1-*one* (*3j*): isolated yield 225 mg (97%); yellowish green solid; mp 263–264 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.63 (1H, s), 8.17 (1H, d, *J* = 7.45 Hz), 7.75 (2H, s), 7.69 (1H, d, *J* = 8.25 Hz), 7.62–7.60 (3H, m), 7.58–7.50 (3H, m), 7.29 (2H, t, *J* = 7.50 Hz), 7.04 (1H, s), 6.90 (1H, t, *J* = 7.08 Hz); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 186.8, 155.2, 147.5, 141.9, 139.1, 138.8, 135.9, 131.5, 130.5, 130.3, 129.3, 128.4, 128.3, 126.6, 126.5, 126.1, 120.8, 120.7, 117.2, 101.6, 96.3; IR (KBr, cm⁻¹) ν 3341, 1604, 1561, 1517, 1468, 1438, 1405; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₆N₃OSCl₂ 464.0391, found 464.0385.

(*Z*)-1-(2,4-*Dimethylphenyl*)-2-(2-(*phenylamino*)-5*H*-benzo[*e*]*pyrazolo*[1,5-*c*][1,3]*thiazin*-5-*ylidene*)*ethan*-1-*one* (**3***k*): isolated yield 178 mg (84%); yellowish green solid; mp 265–267 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.48 (1H, s), 8.15 (1H, d, *J* = 7.75 Hz), 7.72 (2H, d, *J* = 7.80 Hz), 7.60–7.58 (3H, m), 7.55–7.47 (3H, m), 7.30 (2H, t, *J* = 7.83 Hz), 7.16 (1H, d, *J* = 8.00 Hz), 7.13 (1H, s), 7.00 (1H, s), 6.90 (1H, t, *J* = 7.30 Hz), 2.50 (3H, s), 2.33 (3H, s); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 191.2, 154.8, 146.0, 142.0, 140.7, 138.6, 137.8, 136.8, 132.6, 130.3, 129.4, 128.4, 128.1, 127.1, 127.0, 126.5, 120.7, 117.0, 102.1, 95.7, 21.3, 20.8; IR (KBr, cm⁻¹) ν 3285, 1599, 1561, 1518, 1501, 1473, 1437; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₆H₂₂N₃OS 424.1484, found 424.1479.

(Z)-1-(2-(Phenylamino)-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)propan-2-one (**3***I*): isolated yield 127 mg (76%); yellowish green solid; mp 223–224 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.45 (1H, s), 8.10 (1H, d, *J* = 6.40 Hz), 7.65 (1H, d, *J* = 7.10 Hz), 7.61 (1H, d, *J* = 7.00 Hz), 7.49–7.45 (2H, m), 7.33 (2H, s), 7.17 (1H, s), 7.94– 6.91 (2H, m); ¹³C NMR (125 MHz, DMSO- d_6) δ 195.0, 154.7, 144.0, 141.9, 138.5, 130.3, 129.4, 127.8, 127.1, 126.3, 125.8, 120.6, 127.6, 117.0, 102.3, 95.5, 30.9; IR (KBr, cm⁻¹) ν 3307, 1632, 1601, 1567, 1483, 1441, 1306; HRMS (ESI-TOF, [M + H]⁺) calcd for C₁₉H₁₆N₃OS 334.1014, found 334.1025.

(*Z*)-2-(2-(*Phenylamino*)-5*H*-*benzo*[*e*]*pyrazolo*[1,5-*c*][1,3]*thiazin*-5-*ylidene*)-1-(*thiophene-2-yl*)*ethan*-1-one (**3***m*): isolated yield 177 mg (88%); orange solid; mp 280–281 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.54 (1H, s), 8.15 (1H, d, *J* = 7.50 Hz), 7.95 (1H, d, *J* = 4.55 Hz), 7.82 (1H, d, *J* = 2.90 Hz), 7.76 (1H, s), 7.70–7.65 (3H, m), 7.54–7.46 (2H, m), 7.38 (2H, t, *J* = 7.55 Hz), 7.28 (1H, t, *J* = 3.98 Hz), 7.00 (1H, s), 6.94 (1H, t, *J* = 7.10 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 180.1, 155.0, 146.5, 146.3, 141.9, 138.7, 133.7, 130.5, 129.5, 129.4, 128.2, 127.0, 126.6, 126.0, 120.8, 120.6, 117.2, 98.4, 95.9; IR (KBr, cm⁻¹) ν 3334, 1601, 1576, 1558, 1475, 1438, 1401; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₂H₁₆N₃OS₂ 402.0735, found 402.0745.

(*Z*)-2-(2-Amino-5H-benzo[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)-1-phenylethan-1-one (**3n**): isolated yield 177 mg (88%); orange solid; mp >300 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 8.07 (1H, d, *J* = 7.60 Hz), 7.91 (2H, d, *J* = 7.30 Hz), 7.76 (1H, s), 7.70 (1H, d, *J* = 7.75 Hz), 7.61–754 (3H, m), 7.52–7.45 (2H, m), 6.71 (1H, s), 6.12 (2H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.0, 159.3, 147.3, 139.4, 139.2, 132.4, 130.1, 129.2, 128.1, 127.5, 127.0, 126.2, 126.0, 120.9, 97.8, 95.2; IR (KBr, cm⁻¹) ν 3420, 3330, 1620, 1612, 1577, 1499, 1488, 1434, 1405; HRMS (ESI-TOF, $[M + H]^+$) calcd for C₁₈H₁₄N₃OS 320.0858, found 320.0852.

(*Z*)-2-(5*H*-Benzo[*e*]*pyrazolo*[1,5-*c*][1,3]*thiazin*-5-*y*l*idene*)-1-*phenylethan*-1-*one* (**3o**): isolated yield 116 mg (76%); orange solid; mp 182–183 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.20–8.18 (3H, t, *J* = 6.43 Hz), 8.011 (2H, d, *J* = 7.25 Hz), 7.76 (1H, d, *J* = 7.40 Hz), 7.64 (1H, t, *J* = 6.92 Hz), 7.56 (2H, t, *J* = 7.45 Hz), 7.51 (3H, t, *J* = 9.10 Hz); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 187.7, 148.0, 144.3, 138.6, 133.0, 130.3, 129.3, 129.2, 127.9, 126.6, 126.2, 125.9, 121.3, 105.7, 101.1; IR (KBr, cm⁻¹) ν 1623, 1617, 1599, 1578, 1514,1469, 1399; HRMS (ESI-TOF, [M + H]⁺) calcd for C₁₈H₁₃N₂OS 305.0749, found 305.0759.

(*Z*)-2-(8-Fluoro-2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c]-[1,3]thiazin-5-ylidene)-1-phenylethan-1-one (**3p**): isolated yield 192 mg (93%); yellowish green solid; mp 269–270 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.54 (1H, s), 8.27 (1H, s), 7.98 (2H, d, *J* = 6.95 Hz), 7.92 (1H, s), 7.73 (1H, d, *J* = 8.30 Hz), 7.64–7.60 (5H, m), 7.36–7.35 (3H, m), 7.02 (1H, s), 6.94 (1H, t, *J* = 6.90 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.3, 162.5 (d, ¹*J*_{C-F} = 249.6 Hz), 155.0, 146.5, 141.9, 139.1, 138.2, 132.7, 129.5, 129.4, 127.7, 120.8, 117.6, 117.2, 116.0 (d, ²*J*_{C-F} = 22.4 Hz), 112.7 (d, ²*J*_{C-F} = 25.5 Hz), 98.8, 95.8; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –109.1; IR (KBr, cm⁻¹) ν 3329, 1599, 1523, 1497, 1478, 1424; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₇N₃OSF 414.1076, found 414.1089.

(*Z*)-1-(4-Chlorophenyl)-2-(8-fluoro-2-(phenylamino)-5H-benzo-[*e*]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)ethan-1-one (**3***q*): isolated yield 211 mg (94%); yellowish green solid; mp 297–298 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.53 (1H, s), 8.28 (1H, q, *J* = 8.40 Hz, *J* = 5.45 Hz), 7.98 (2H, d, *J* = 8.25 Hz), 7.88 (1H, s), 7.78 (1H, d, *J* = 7.60 Hz), 7.67 (2H, d, *J* = 5.25 Hz), 7.62 (2H, d, *J* = 7.95 Hz), 7.39–7.36 (3H, m), 7.03 (1H, s), 6.94 (1H, t, *J* = 7.25 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 186.1, 162.6 (d, ¹*J*_{C-F} = 248.8 Hz), 155.1, 147.1, 141.9, 138.3, 137.8, 137.6, 129.6, 129.3, 120.9, 117.6, 117.3, 116.2 (d, ²*J*_{C-F} = 22.8 Hz), 112.7 (d, ²*J*_{C-F} = 24.9 Hz), 98.5, 96.0; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –109.1; IR (KBr, cm⁻¹) ν 3303, 1602, 1552, 1516, 1495, 1480, 1426; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₄H₁₆N₃OSCIF 448.0687, found 448.0684.

(*Z*)-2-(8-Fluoro-2-(phenylamino)-5H-benzo[e]pyrazolo[1,5-c]-[1,3]thiazin-5-ylidene)-1-(4-methoxyphenyl)ethan-1-one (**3r**): isolated yield 197 mg (89%); yellowish green solid; mp >300 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 9.51 (1H, s), 8.21 (1H, s), 7.94 (2H, d, *J* = 7.65 Hz), 7.88 (1H, s), 7.69 (1H, d, *J* = 8.10 Hz), 7.63 (2H, d, *J* = 7.05 Hz), 7.37–7.33 (3H, m), 7.11 (2H, d, *J* = 7.70 Hz), 6.98 (1H, s), 6.93 (1H, s), 3.86 (3H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 186.1, 162.5 (d, ¹*J*_{C-F} = 248.6 Hz), 163.0, 154.8, 145.6, 142.0, 138.0, 131.7, 129.8, 129.5, 129.1, 120.7, 117.6, 117.1, 115.8 (d, ²*J*_{C-F} = 24.9 Hz), 114.6, 112.5 (d, ²*J*_{C-F} = 24.8 Hz), 98.8, 95.5, 56.0; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –109.3; IR (KBr, cm⁻¹) ν 3317, 1598, 1556, 1510, 1489, 1428; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₅H₁₉N₃O₂SF 444.1182, found 444.1185.

(Z)-2-(8-Fluoro-2-((4-(trifluoromethyl)phenyl)amino)-5H-benzo-[e]pyrazolo[1,5-c][1,3]thiazin-5-ylidene)-1-phenylethan-1-one (**35**): isolated yield 226 mg (94%); yellowish green solid; mp >300 °C; ¹H NMR (500 MHz, DMSO- d_6) δ 10.02 (1H, s), 8.26 (1H, s), 8.00 (2H, d, J = 7.15 Hz), 7.94 (1H, s), 7.80–7.45 (3H, m), 7.72–7.71 (2H, m), 7.65–7.61 (3H, m), 7.37 (1H, s), 7.05 (1H, s); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.5, 162.6 (d, ¹ J_{C-F} = 248.0 Hz), 154.2, 146.6, 145.3, 138.9, 138.4, 132.8, 129.9, 129.8, 129.4, 129.3, 129.2, 127.8, 126.7, 120.7, 117.5, 116.8, 116.0 (d, ² J_{C-F} = 22.3 Hz), 112.7 (d, ² J_{C-F} = 25.8 Hz), 99.2, 96.0; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –59.6 (3F, s), –109.0 (1F, s); IR (KBr, cm⁻¹) ν 3307, 1608, 1598, 1561, 1519, 1480, 1414, 1329, 1261, 1111, 1069, 998; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₅H₁₆N₃OSF₄ 482.0950, found 482.0962.

(*Z*)-2-(2-((4-Ethoxyphenyl)amino)-8-fluoro-5H-benzo[e]pyrazolo-[1,5-c][1,3]thiazin-5-ylidene)-1-phenylethan-1-one (**3t**): isolated yield 211 mg (92%); yellowish green solid; mp 271–272 °C; ¹H NMR (500 MHz, DMSO- d_{6}) δ 9.28 (1H, s), 8.26 (1H, q, *J* = 8.76 Hz, *J* = 5.5 Hz), 7.97 (2H, d, *J* = 6.85 Hz), 7.90 (1H, s), 7.77 (1H, q, *J* = 9.10 Hz, *J* = 2.25 Hz), 7.64–7.59 (3H, m), 7.54 (2H, d, *J* = 8.90 Hz), 7.39–7.35 (1H, m), 6.96 (1H, s), 6.95 (2H, s), 4.00 (2H, q, J = 6.93 Hz), 1.33 (3H, d, J = 6.95 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ 187.2, 162.5 (d, ${}^1J_{C-F} = 248.4$ Hz), 155.3, 153.2, 146.4, 139.0, 138.1, 135.2, 132.6, 129.7 (d, ${}^3J_{C-F} = 8.1$ Hz), 129.3, 129.1 (d, ${}^3J_{C-F} = 8.1$ Hz), 127.6, 118.7, 117.6, 116.0 (d, ${}^2J_{C-F} = 22.3$ Hz), 115.4, 112.5 (d, ${}^2J_{C-F} = 25.6$ Hz), 98.4, 95.5, 63.6, 15.2; ¹⁹F NMR (376 MHz, DMSO- d_6) δ –109.2; IR (KBr, cm⁻¹) ν 3339, 1607, 1566, 1513, 1495, 1464, 1438, 1413; HRMS (ESI-TOF, [M + H]⁺) calcd for C₂₆H₂₁N₃O₂SF 458.1339, found 458.1342.

ASSOCIATED CONTENT

S Supporting Information

 1 H, 19 F, and 13 C NMR spectra of all new compounds and X-ray data for compound **3k** in CIF format. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b00288.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: wenlirong@qust.edu.cn. *E-mail: liming928@qust.edu.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was financially supported by the National Natural Science Foundation of China (Grants 21372137 and 21072110) and the Natural Science Foundation of Shandong Province (Grants ZR2012BM003 and ZR2014BM006).

REFERENCES

(1) Birck, M. R.; Holler, T. P.; Woodard, R. W. J. Am. Chem. Soc. 2000, 122, 9334–9335.

- (2) (a) Duckworth, B. P.; Aldrich, C. C. Anal. Biochem. 2010, 403, 13–19. (b) Foley, T. L.; Yasgar, A.; Garcia, C. J.; Jadhav, A.; Simeonov, A.; Burkart, M. D. Org. Biomol. Chem. 2010, 8, 4601–4606.
- (3) Mizuhara, T.; Oishi, S.; Ohno, H.; Shimura, K.; Matsuoka, M.; Fujii, N. *Bioorg. Med. Chem.* **2012**, *20*, 6434–6441.
- (4) Solomon, V. R.; Haq, W.; Srivastava, K.; Puri, S. K.; Katti, S. B. J. Med. Chem. 2007, 50, 394–398.

(5) Lombardino, J. G.; McLamore,W. M.; Lanbach, G. D. US2985649A, 1961.

(6) Hamley, P.; Tinker, A. PCT Int. Appl. WO 00/06576, 2000.

(7) Cecchetti, V.; Filipponi, E.; Fravolini, A.; Tabarrini, O.; Xin, T. Bioorg. Med. Chem. **1997**, 5, 1339–1434.

(8) Fodor, L.; Szabó, J.; Bernáth, G.; Sohár, P.; Maclean, D. B.; Smith, R. W.; Ninomiya, I.; Naito, T. J. Heterocycl. Chem. **1989**, 26, 333–337.

(9) Chen, H.; Hao, L.; Zhu, M.; Yang, T. Y.; Wei, S. N.; Qin, Z. B.;
Zhang, P. Z.; Li, X. L. *Bioorg. Med. Chem. Lett.* 2014, 24, 3426–3429.
(10) (a) Hardy, S.; Martin, S. F. Org. Lett. 2011, 13, 3102–3105.
(b) Unsworth, W. P.; Kitsiou, C.; Taylor, R. J. K. Org. Lett. 2013, 15, 258–261. (c) Hucher, N.; Decroix, B.; Daïch, A. J. Org. Chem. 2001, 66, 4695–4703. (d) Xia, Z. M.; Wang, K.; Zheng, J. N.; Ma, Z. Y.; Jiang, Z. G.; Wang, X. X.; Lv, X. Org. Biomol. Chem. 2012, 10, 1602–1611. (e) Kitsiou, C.; Unsworth, W. P.; Coulthard, G.; Taylor, R. J. K. Tetrahedron 2014, 70, 7172–7180. (f) Jarvis, C. L.; Richers, M. T.; Breugst, M.; Houk, K. N.; Seidel, D. Org. Lett. 2014, 16, 3556–3559.

(11) (a) Beletskaya, I. P.; Ananikov, V. P. Chem. Rev. 2011, 111, 1596–1636. (b) Liu, H.; Jiang, X. F. Chem.—Asian J. 2013, 8, 2546–2563. (c) Lee, C. F.; Liu, Y. C.; Badsara, S. S. Chem.—Asian J. 2014, 9, 706–722. (d) Kwong, F. Y.; Buchwald, S. L. Org. Lett. 2002, 4, 3517–3520. (e) Fernández-Rodríguez, M. A.; Shen, Q.; Hartwig, J. F. J. Am. Chem. Soc. 2006, 128, 2180–2181. (f) Hartwig, J. F. Acc. Chem. Res. 2008, 41, 1534–1544.

(12) (a) Park, N.; Park, K.; Jang, M.; Lee, S. J. Org. Chem. 2011, 76, 4371–4378. (b) Qiao, Z. J.; Liu, H.; Xiao, X.; Fu, Y. N.; Wei, J. P.; Li, Y. X.; Jiang, X. F. Org. Lett. 2013, 15, 2594–2597.

(13) (a) Yadav, J.; Reddy, B.; Reddy, Y.; Praneeth, K. Synthesis 2009, 1520–1524. (b) Fang, X.; Tang, R.; Zhong, P.; Li, J. Synthesis 2009, 4183–4189.

(14) (a) Ma, D. W.; Cai, Q. Acc. Chem. Res. 2008, 41, 1450-1460. (b) Ma, D. W.; Lu, X.; Shi, L.; Zhang, H.; Jiang, Y. W.; Liu, X. Q. Angew. Chem., Int. Ed. 2011, 50, 1118–1121. (c) Ma, D. W.; Geng, Q.; Zhang, H.; Jiang, Y. W. Angew. Chem., Int. Ed. 2010, 49, 1291-1294. (d) Zhou, A. X.; Liu, X. Y.; Yang, K.; Zhao, S. C.; Liang, Y. M. Org. Biomol. Chem. 2011, 9, 5456-5462. (e) Zhang, X. Y.; Zeng, W. L.; Yang, Y.; Huang, H.; Liang, Y. Org. Lett. 2014, 16, 876-879. (f) He, Y. T.; Li, L. H.; Yang, Y. F.; Wang, Y. Q.; Luo, J. Y.; Liu, X. Y.; Liang, Y. M. Chem. Commun. 2013, 49, 5687-5689. (g) Lv, X.; Liu, Y.; Qian, W.; Bao, W. L. Adv. Synth. Catal. 2008, 350, 2507-2512. (h) Ke, F.; Qu, Y. Y.; Jiang, Z. Q.; Li, Z. K.; Wu, D.; Zhou, X. G. Org. Lett. 2011, 13, 454-457. (i) Deng, H.; Li, Z.; Ke, F.; Zhou, X. Chem. Eur.-J. 2012, 18, 4840-4843. (j) Ke, F.; Qu, Y.; Jiang, Z.; Li, Z.; Wu, D.; Zhou, X. G. Org. Lett. 2011, 13, 454-457. (k) Chen, C. K.; Chen, Y. W.; Lin, C. H.; Lin, H. P.; Lee, C. F. Chem. Commun. 2010, 46, 282-284. (1) Cheng, J. H.; Yi, C. L.; Liu, T. J.; Lee, C. F. Chem. Commun. 2012, 48, 8440-8442. (m) Kao, H. L.; Lee, C. F. Org. Lett. 2011, 13, 5204-5207.

(15) (a) You, W.; Yan, X. Y.; Liao, Q.; Xi, C. J. Org. Lett. **2010**, *12*, 3930–3933. (b) Wang, F.; Cai, S. J.; Wang, Z. P.; Xi, C. J. Org. Lett. **2011**, *13*, 3202–3205. (c) S. Murru, H.; Ghosh, S. K.; Sahoo, B.; K, Patel. Org. Lett. **2009**, *11*, 4254–4257. (d) Ma, D.; Xie, S.; Xue, P.; Zhang, X.; Dong, J.; Jiang, Y. Angew. Chem., Int. Ed. **2009**, *48*, 4222–4225.

(16) Singh, M. S.; Nandib, G. C.; Chandaa, T. RSC adv. 2013, 3, 14183-14198.

(17) (a) Samuel, R.; Chandran, P.; Retnamma, S.; Sasikala, K. A.; Sreedevi, N. K.; Anabha, E. R.; Asokan, C. V. *Tetrahedron* **2008**, *64*, 5944–5948. (b) Nandi, G. C.; Samai, S.; Singh, M. S. J. Org. Chem. **2011**, *76*, 8009–8014.

(18) (a) Mathew, P.; Asokan, C. V. *Tetrahedron Lett.* **2005**, *46*, 475–478. (b) Mathew, P.; Asokan, C. V. *Tetrahedron* **2006**, *62*, 1708–1716.

- (19) (a) Verma, R. K.; Verma, G. K.; Shukla, G.; Nagaraju, A.; Singh,
- M. S. ACS Comb. Sci. 2012, 14, 224–230. (b) Chowdhury, S.; Nandi,
- G. C.; Samai, S.; Singh, M. S. Org. Lett. 2011, 13, 3762–3765.
 (20) Rahman, A.; Ila, H.; Junjappa, H. Synthesis 1984, 250–252.
- (21) Samuel, R.; Asokan, C. V.; Suma, S.; Chandran, P.; Retnamma, S.; Anabha, E. R. *Tetrahedron Lett.* **2007**, *48*, 8376–8378.
- (22) (a) Peruncheralathan, S.; Khan, T. A.; Ila, H.; Junjappa, H. J. Org. Chem. 2005, 70, 10030–10035. (b) Nandi, G. C.; Singh, M. S.; Ila, H.; Junjappa, H. Eur. J. Org. Chem. 2012, 967–974.
- (23) Abdelhamid, A. O.; Ismail, Z. H.; Abdel-Gawad, S. M.; Ghorab, M. M.; Abdel-Aziem, A. *Phosphorus, Sulfur Silicon Relat. Elem.* **2009**, 184, 58–75.

(24) (a) Singh, O. M.; Devi, N. S. J. Org. Chem. 2009, 74, 3141–3144. (b) Nandi, G. C.; Samai, S.; Singh, M. S. J. Org. Chem. 2010, 75, 7785–7795.

(25) (a) Singh, O. M.; Devi, N. S.; Thokchom, D. S.; Sharma, G. J. *Eur. J. Med. Chem.* 2010, 45, 2250–2257. (b) Verma, R. K.; Verma, G. K.; Raghuvanshi, K.; Singh, M. S. *Tetrahedron* 2011, 67, 584–589. (c) Verma, R. K.; Prajapati, V. K.; Verma, G. K.; Chakraborty, D.; Sundar, S.; Rai, M.; Dubey, V. K.; Singh, M. S. *ACS Med. Chem. Lett.* 2012, 3, 243–247.

(26) (a) Wen, L. R.; Li, Z. R.; Li, M.; Cao, H. Green Chem. **2012**, *14*, 707–716. (b) Wen, L. R.; Men, L. B.; He, T.; Ji, G. J.; Li, M. Chem.— Eur. J. **2014**, 20 (17), 5028–5033. (c) Wen, L. R.; Jin, X. J.; Niu, X. D.; Li, M. J. Org. Chem. **2015**, 80, 90–98. (d) Li, M.; Cao, H.; Wang, Y.; Lv, X. L.; Wen, L. R. Org. Lett. **2012**, *14*, 3470–3473. (e) Wen, L. R.; He, T.; Lan, M. C.; Li, M. J. Org. Chem. **2013**, 78, 10617–10628. (f) Wen, L. R.; Li, S. L.; Zhang, J.; Li, M. Green Chem. **2015**, *17*, 1581– 1588.

(27) García-Orozco, I.; Ortega-Alfaro, M. C.; López-Cortés, J. G.; Toscano, R. A.; Alvarez-Toledano, C. Inorg. Chem. 2006, 45, 1766-

1773. (Note: The authors mistakenly identified as carbonyl enolization of thiocarbonyl.)

(28) (a) Tye, J. W.; Weng, Z. Q.; Johns, A. M.; Incarvito, C. D.; Hartwig, J. F. *J. Am. Chem. Soc.* **2008**, *130*, 9971–9983. (b) Suri, M.; Jousseaume, T.; Neumanna, J. J.; Glorius, F. *Green Chem.* **2012**, *14*, 2193–2196.

(29) Kim, I.; Song, J. H.; Park, C. M.; Jeong, J. W.; Kim, H. R.; Ha, J. R.; No, Z.; Hyun, Y. L.; Cho, Y. S.; Kang, N. S.; Jeon, D. J. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 922–926.

(30) Kiss, L. E.; Learmonth, D. A.; Rosa, C. P. D. C. P.; Gusmao de Noronha, R.; Palma, P. N. L.; Soares da Silva, P. M. V. A.; Beliaev, A. PCT Int. Appl. (2010), WO 2010074588 A2 20100701.

NOTE ADDED AFTER ASAP PUBLICATION

Reference 16 was added April 30, 2015.